2001 News Archive
Holding in Company
24 December 2001
The Company received notification from Nomura International Plc informing them that they no longer have a notifiable interest in the Company~s issued ordinary share capital.
Holding in Company
24 December 2001
Protherics received today a notification from M&G Investment Management Limited informing them that Prudential plc and certain of its subsidiary companies have a notifiable interest
Additional Listing
21 December 2001
Protherics PLC ("Protherics") announces that Wingate Capital Ltd ("Wingate") and Fisher Capital Ltd ("Fisher") have, following conversion notices served
Director Shareholding
19 December 2001
Notification of interests OF Directors AND CONNECTED PERSONS
Doc re Supp. Listing Parts
18 December 2001
Doc Re Issued in relation to the Admission to the Official List of the UK Listing Authority and to trading on the London Stock Exchange
Holding in Company
17 December 2001
Notification of major interests in shares
Additional Listing
14 December 2001
Protherics PLC ("Protherics") announces that Wingate Capital Ltd ("Wingate") and Fisher Capital Ltd ("Fisher") have, following conversion notices served on 11 December 2001 converted £500,000 in principal amount
Additional Listing
22 November 2001
Protherics PLC ("Protherics") announces that Wingate Capital Ltd ("Wingate") and Fisher Capital Ltd ("Fisher") have, following conversion notices served on 21st November 2001 converted £133,000 in principal amount (together with £7847 in interest) and £248,000 in principal amount (together with £14,632 in interest) of the unsecured convertible debentures issued by Protherics (the "Convertible Debentures") held by them into 704,235 and 1,313,160 ordinary shares of 2p each in Protherics respectively.
Additional Listing
08 November 2001
Protherics PLC ("Protherics") announces that Wingate Capital Ltd ("Wingate") and Fisher Capital Ltd ("Fisher") have, following conversion notices served on 5th November 2001 converted £42,000 in principal amount (together with £2,403 in interest) and £78,000 in principal amount (together with £4,463 in interest) of the unsecured convertible debentures issued by Protherics (the "Convertible Debentures") held by them into 227,709 and 422,889 ordinary shares of 2p each in Protherics respectively.
Doc re Listing Particulars
07 November 2001
Doc Re Listing Particulars for the Admission to the Official List of the UK Listing Authority and to trading on the London Stock Exchange of up to 46,540,110 New Ordinary Shares to be issued on conversion of the Convertible Debentures.
Notification of major interests in shares
17 October 2001
The Company was notified today by Bradshaw Asset Management Limited on behalf of Victory Capital plc that following a purchase of 3,450,000 shares, they now have a holding of 8,950,000 ordinary shares, representing 5.14% of the issued share capital of the Company.
Doc re Form 20-F
01 October 2001
Doc Re Form 20-F for the fiscal year ended March 31, 2001
Annual General Meeting Statement
27 September 2001
Stuart Wallis, Chairman of Protherics plc, made this statement following the company~s Annual General Meeting held today.
Protherics receives 2nd FDA approval in less than a year
03 September 2001
Protherics PLC announces today that DigiFab™, its treatment for digoxin toxicity, which can result in serious and sometimes fatal disturbances of heart function.
Protherics Preliminary Results
19 July 2001
Protherics PLC, a UK immunotherapeutics company, today announces its preliminary results for the year ended 31 March 2001.
Protherics agrees sale of CAMD business for US$ 9.4 million
12 July 2001
Protherics PLC ("Protherics" or the "Company") announces the sale of its Computer-Aided Molecular Design ("CAMD") operations to Tularik Inc., a San Francisco based drug discovery company, for 400,000 Tularik shares with a current value of approximately US $9.4 million.
Enfer agrees deal with Abbott Laboratories for International distribution of BSE test
16 March 2001
Enfer Scientific Ltd has signed an agreement for Abbott Laboratories to undertake the international distribution of the Protherics/Enfer post-mortem BSE test-kit.
Cash Placing of 7,829,007 new ordinary shares at 40 pence per share
29 January 2001
Protherics PLC ("Protherics" or the "Company") announces that it has today raised approximately £3.1 million through a placing of 7,829,007 new ordinary shares of 2 pence each in the Company (the "New Shares") at a price of 40 pence per share with institutional investors (the "Placing") which has been underwritten by WestLB Panmure Limited.
2008 News
2007 News Archive
2006 News Archive
2005 News Archive
2004 News Archive
2003 News Archive
2002 News Archive
2001 News Archive
2000 News Archive